Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
